Pralsetinib | CAS 2097132-94-8 - Request Quote
Pralsetinib
| SZ CAT No: | SZ-P164001 |
| CAS No | 2097132-94-8 |
| Mol.F. | C27H32FN9O2 |
| Mol.Wt. | 533.6 |
| Inv. Status | Synthesis on demand |
| Shipping Condition | Room Temperature |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Pralsetinib is chemically (1s,4R)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)cyclohexane-1-carboxamide. Pralsetinib is supplied with detailed characterization data compliant with regulatory guideline. Pralsetinib can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Pralsetinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 2097132-94-8
Purchase 2097132-94-8
Order 2097132-94-8
Enquire 2097132-94-8
price of 2097132-94-8
2097132-94-8 Supplier
2097132-94-8 Manufacturer
2097132-94-8 Exporter
buy high quality Pralsetinib
Purchase Pralsetinib
Pralsetinib suppliers
Pralsetinib manufacturers
Pralsetinib price
Order Pralsetinib
Enquire Pralsetinib
Pralsetinib cost
Pralsetinib Supplier
Pralsetinib Distributor
Pralsetinib for Method Validation
Pralsetinib Reference Standard
Pralsetinib for ANDA Filing
Pralsetinib for Forced Degradation Studies
Pralsetinib Identification Standards
Pralsetinib for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.